Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

Post-translational modification profiling – A novel tool for mapping the protein modification landscape in cancer

Advances of Proteomics in Novel PTM Discovery: Applications in Cancer Therapy

Pan-cancer Analysis of Post-Translational Modifications Reveals Shared Patterns of Protein Regulation.

Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers

Protein post-translational modifications in the regulation of cancer hallmarks

Emerging Role of Protein Post-Translational Modification in the Potential Clinical Application of Cancer

Proteomic approaches for the profiling of ubiquitylation events and their applications in drug discovery

Profiling Of Post-Translational Modifications By Chemical And Computational Proteomics

Exploring the Role of Unconventional Post-Translational Modifications in Cancer Diagnostics and Therapy

Comprehensive Profiling of Protein Ubiquitination for Drug Discovery

Exploring Protein Post-Translational Modifications of Breast Cancer Cells Using a Novel Combinatorial Search Algorithm

Proteomic identification of protein ubiquitination events

Unraveling the battle for lysine: A review of the competition among post-translational modifications

The role of ubiquitination in tumorigenesis and targeted drug discovery

Advances in post-translational modifications of proteins and cancer immunotherapy

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

Unconventional protein post-translational modifications: the helmsmen in breast cancer

Integrating the analysis of human biopsies using post‐translational modifications proteomics

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers

Dissecting the Ubiquitin Pathway by Mass Spectrometry.

Current methodologies in protein ubiquitination characterization: from ubiquitinated protein to ubiquitin chain architecture